


# Non Muscle Invasive Bladder Cancer Pipeline 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

NMIBC Companies are Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Pfizer, and others.

ALBANY, NEW YORK, UNITED STATES, March 21, 2024 /EINPresswire.com/ --

As per DelveInsight's assessment, globally, Non Muscle Invasive Bladder Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ Non Muscle

Invasive Bladder Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.



The Pipeline report for Non-Muscle Invasive Bladder Cancer provides a thorough evaluation of commercial and clinical aspects of pipeline products, spanning from pre-clinical development to market availability. It includes an extensive overview of each drug, detailing its mechanism of action, clinical studies, potential NDA approvals, and various product development activities. These encompass technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details related to the product's development.

[“Non Muscle Invasive Bladder Cancer Pipeline Insight, 2024”](#) report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non Muscle Invasive Bladder Cancer Market.

Some of the key takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Report: Non Muscle Invasive Bladder Cancer Companies across the globe are diligently working toward developing novel Non Muscle Invasive Bladder Cancer treatment therapies with a considerable amount of success over the years.

Non Muscle Invasive Bladder Cancer companies working in the treatment market are Tollys, Aura

Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others, are developing therapies for the Non Muscle Invasive Bladder Cancer treatment

Emerging Non Muscle Invasive Bladder Cancer therapies in the different phases of clinical trials are- TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others are expected to have a significant impact on the Non Muscle Invasive Bladder Cancer market in the coming years.

In April 2022, A Phase I study of the Erdafitinib intravesical delivery system (TAR-2110) was started by Janssen Research & Development, LLC in patients with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer with Selected FGFR Mutations or Fusions.

UGN-102 (mitomycin gel) is a formulation under investigation, employing our advanced RTGel reverse-thermal hydrogel technology. It is currently undergoing Phase III clinical assessment for treating Non-Muscle Invasive Bladder Cancer, specifically focusing on low-grade NMIBC.

Sasanlimab (PF-06801591) is an immunotherapeutic agent in development by Pfizer for various cancer types. It falls under the category of anti-PD-1 treatments, working to inhibit the PD-1 protein found on immune T-cells' surface, which may occasionally target healthy cells.

#### Non Muscle Invasive Bladder Cancer Overview

Cancer is identified in the tissue that borders the inner surface of the bladder and is referred to as non-muscle invasive bladder cancer (NMIBC). The muscle in the bladder is not implicated. The sixth most prevalent cancer in the US is bladder cancer. In 2020, bladder cancer will be discovered in close to 81,000 Americans. Males are more likely than females to develop bladder cancer.

Emerging Non Muscle Invasive Bladder Cancer Drugs Under Different Phases of Clinical Development Include:

TL-532: Tollys

AU-011: Aura Biosciences

TARA-002: Protara Therapeutics

VAX 014: Vaxiion Therapeutics

Pemigatinib: Incyte Corporation

Erdafitinib: Janssen Pharmaceuticals

TLD 1433: Theralase Technologies

PF-06801591: Pfizer

Nivolumab: BristolMyers Squibb

APL-1202: Asieris Pharmaceuticals

#### Non Muscle Invasive Bladder Cancer Route of Administration

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral  
Parenteral  
Intravenous  
Subcutaneous  
Topical

Non Muscle Invasive Bladder Cancer Molecule Type

Non Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types, such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Download Sample PDF Report to know more about [Non Muscle Invasive Bladder Cancer drugs and therapies](#)

Non Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment

Non Muscle Invasive Bladder Cancer Assessment by Product Type

Non Muscle Invasive Bladder Cancer By Stage and Product Type

Non Muscle Invasive Bladder Cancer Assessment by Route of Administration

Non Muscle Invasive Bladder Cancer By Stage and Route of Administration

Non Muscle Invasive Bladder Cancer Assessment by Molecule Type

Non Muscle Invasive Bladder Cancer by Stage and Molecule Type

DelveInsight's Non Muscle Invasive Bladder Cancer Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Some of the key companies in the Non Muscle Invasive Bladder Cancer Therapeutics Market include:

Key companies developing therapies for Non Muscle Invasive Bladder Cancer are – Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong Biomedical, Spectrum Pharmaceuticals, FKD therapies,

Altor Biosciences, Heat Biologics, EMD Sereno, QED Therapeutics, and others.

#### Non Muscle Invasive Bladder Cancer Pipeline Analysis:

The Non Muscle Invasive Bladder Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Non Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Muscle Invasive Bladder Cancer Treatment.

Non Muscle Invasive Bladder Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Non Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Muscle Invasive Bladder Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF Report for [Non Muscle Invasive Bladder Cancer Pipeline Assessment and clinical trials](#)

#### Non Muscle Invasive Bladder Cancer Pipeline Market Drivers

Increase in the number of patients suffering from non-muscle invasive bladder cancer.

Approximately 70-75% bladder cancers are non-muscle invasive bladder cancer (NMIBC), development of novel therapies and favorable government policies are some of the important factors that are fueling the Non Muscle Invasive Bladder Cancer Market.

#### Non Muscle Invasive Bladder Cancer Pipeline Market Barriers

However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Non Muscle Invasive Bladder Cancer Market growth.

#### Scope of Non Muscle Invasive Bladder Cancer Pipeline Drug Insight

Coverage: Global

Key Non Muscle Invasive Bladder Cancer Companies: Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others

Key Non Muscle Invasive Bladder Cancer Therapies: TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others

Non Muscle Invasive Bladder Cancer Therapeutic Assessment: Non Muscle Invasive Bladder Cancer current marketed and Non Muscle Invasive Bladder Cancer emerging therapies  
Non Muscle Invasive Bladder Cancer Market Dynamics: Non Muscle Invasive Bladder Cancer market drivers and Non Muscle Invasive Bladder Cancer market barriers

Request for Sample Report @ [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=apr](https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr)

## Table of Contents

1. Non Muscle Invasive Bladder Cancer Report Introduction
2. Non Muscle Invasive Bladder Cancer Executive Summary
3. Non Muscle Invasive Bladder Cancer Overview
4. Non Muscle Invasive Bladder Cancer- Analytical Perspective In-depth Commercial Assessment
5. Non Muscle Invasive Bladder Cancer Pipeline Therapeutics
6. Non Muscle Invasive Bladder Cancer Late Stage Products (Phase II/III)
7. Non Muscle Invasive Bladder Cancer Mid Stage Products (Phase II)
8. Non Muscle Invasive Bladder Cancer Early Stage Products (Phase I)
9. Non Muscle Invasive Bladder Cancer Preclinical Stage Products
10. Non Muscle Invasive Bladder Cancer Therapeutics Assessment
11. Non Muscle Invasive Bladder Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non Muscle Invasive Bladder Cancer Key Companies
14. Non Muscle Invasive Bladder Cancer Key Products
15. Non Muscle Invasive Bladder Cancer Unmet Needs
- 16 . Non Muscle Invasive Bladder Cancer Market Drivers and Barriers
17. Non Muscle Invasive Bladder Cancer Future Perspectives and Conclusion
18. Non Muscle Invasive Bladder Cancer Analyst Views
19. Appendix
20. About DelveInsight

## About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Ankit Nigam

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/697672769>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.